AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19320234
Drug: BILB 1941
RxNorm normalized name: Bilberry
DrugBank: Bilberry (DB14235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BILB 1941 200 mg
Trial: 19320234
Drug: BILB 1941
RxNorm normalized name: Bilberry
DrugBank: Bilberry (DB14235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BILB 1941 300 mg
Trial: 19320234
Drug: BILB 1941
RxNorm normalized name: Bilberry
DrugBank: Bilberry (DB14235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BILB 1941 450 mg
Trial: 9333147
Drug: Didanosine (ddI)
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Didanosine (ddI) plus hydroxyurea (HU) combination therapy
Trial: 8226485
Drug: Caffeine (CAF)
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine (CAF) 2 x 2.5 mg/kg x day-1
Trial: 3801360
Drug: Norethisterone 5
RxNorm normalized name: Norethisterone 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norethisterone 5 mg/day
Trial: 3801360
Drug: Norethisterone 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norethisterone 2.5 mg/day
Trial: 23540683
Drug: l-lactate infusion
RxNorm normalized name: L-lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-lactate infusion (target concentration 3 mmol/L)
Trial: 7893268
Drug: Multiple dose
RxNorm normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose powder inhaler (MDPI; Easyhaler)
Trial: 8177971
Drug: Conventional metered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional metered dose inhaler (MDI)
Trial: 2688081
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium retard 100 mg
Trial: 30051975
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg LY2495655 plus placebo
Trial: 30051975
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg LY2495655 plus placebo
Trial: 30051975
Drug: LY2495655 (either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2495655 (either dose)
Trial: 27708124
Drug: Cherry Crush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cherry Crush (CC), Piña Colada (PC), Peach Schnapps (PS)
Trial: 24737415
Drug: Adjuvant imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant imatinib 400 mg/day for 12 months
Trial: 24737415
Drug: Adjuvant imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant imatinib 400 mg/day for 36 months
Trial: 18675959
Drug: GnRHa/chemotherapy cotreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRHa/chemotherapy cotreatment
Trial: 18065071
Drug: Sequential practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential practice trials with short movement goal
Trial: 18065071
Drug: Sequential practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential practice trials with long movement goal
Trial: 18065071
Drug: Separate planning
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate planning of sequential aiming movements
Trial: 15736608
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg or 400 mg of modafinil
Trial: 8732145
Drug: Chinese integrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese integrated medicine (CIM)
Trial: 413493
Drug: Nebulized sodium
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized sodium cromoglycate solution
Trial: 28430159
Drug: Low-molecular-weight fucoidan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight fucoidan (LMF) as a supplemental therapy to chemotarget agents
Trial: 28430159
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (chemotarget agents only)
Trial: 17934385
Drug: Careful selection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Careful selection of medications and routine screening for cardiovascular risk factors
Trial: 11408152
Drug: Intelisite capsule
RxNorm normalized name: AVOBENZONE 30 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 80 mg in 1 mL TOPICAL CREAM [Intensite Creme Lustre Day SPF 30 US]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intelisite capsule
Trial: 9562581
Drug: Toxic effects
RxNorm normalized name: Ellis Tonic
DrugBank: Zinc sulfate, unspecified form (DB14548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toxic effects of therapy
Trial: 7092136
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous dose of metronidazole
Trial: 28993069
Drug: Combination A
RxNorm normalized name: SUNFLOWER OIL 7.92 g in 14 g TOPICAL STICK [OrgaPlus Super Care Balm for combination and oi ly skin type 14g]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination A (silicone-hydrogel CLs)
Trial: 28993069
Drug: Combination B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination B (silicone-hydrogel CLs)
Trial: 25775634
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream applied to a representative plaque for 9 months
Trial: 15962065
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of ketoprofen 100 mg (Group C)
Trial: 15962065
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of tenoxicam 40 mg (Group T)
Trial: 15962065
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of physiological serum 0.9% (Group F)
Trial: 14756017
Drug: Supervised physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised physical training (daily exercise program for 21 +/- 10 days)
Trial: 10477986
Drug: Pain‐Free (oxalate‐containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain‐Free (oxalate‐containing pre‐polymerized resin suspension)
Trial: 10477986
Drug: DentinBloc (0.7%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DentinBloc (0.7% fluoride solution)
Trial: 3834830
Drug: Suppositories containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppositories containing sodium salicylate and Brij 35
Trial: 3834830
Drug: Suppositories without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suppositories without adjuvants
Trial: 3834830
Drug: Suppositories (general)
RxNorm normalized name: Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppositories (general)
Trial: 31578173
Drug: Apalutamide (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apalutamide (four 60 mg tablets, once daily)
Trial: 24383843
Drug: imatinib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: imatinib 800 mg daily (IM800)
Trial: 24383843
Drug: imatinib 400
RxNorm normalized name: imatinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: imatinib 400 mg daily (IM400)
Trial: 26428486
Drug: Donor lymphocyte
RxNorm normalized name: Therapeutic allogeneic lymphocytes
DrugBank: Therapeutic allogeneic lymphocytes (DB17459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donor lymphocyte infusions
Trial: 16163089
Drug: Topical negative-pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical negative-pressure therapy with no interface dressing
Trial: 16163089
Drug: Topical negative-pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical negative-pressure therapy with Vaseline-impregnated gauze
Trial: 16163089
Drug: Topical negative-pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical negative-pressure therapy with nonadherent silicone dressing
Trial: 16163089
Drug: Topical negative-pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical negative-pressure therapy with mylar polyester film dressing
Trial: 12393106
Drug: Warfarin prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin prophylaxis and epidural analgesia
Trial: 1874490
Drug: Chenodiol therapy
RxNorm normalized name: chenodeoxycholate
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodiol therapy
Trial: 1874490
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (similar chenodiol doses, no liver injury)
Trial: 23474008
Drug: Far infrared
RxNorm normalized name: Menthol/Methyl Salicylate 3%-0.5% Topical application Patch, Extended Release [GOLDEN SUNSHINE FAR INFRARED HOT HERBAL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Far infrared therapy (40 minutes, 3 times weekly for a year)
Trial: 23474008
Drug: Far infrared
RxNorm normalized name: Menthol/Methyl Salicylate 3%-0.5% Topical application Patch, Extended Release [GOLDEN SUNSHINE FAR INFRARED HOT HERBAL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Far infrared therapy
Trial: 21357380
Drug: High isoflavone
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High isoflavone intake (>16.3 mg isoflavones)
Trial: 9973149
Drug: Amitriptyline (AMI;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (AMI; 25-37.5 mg)
Trial: 9973149
Drug: Moclobemide (MOCLO;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (MOCLO; 450-600 mg)
Trial: 7977094
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose t-PA
Trial: 7977094
Drug: Accelerated dose
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated dose t-PA
Trial: 2908486
Drug: Control saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control saline solution
Trial: 2908486
Drug: Histamine: aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine: aqueous solution (Hsol)
Trial: 30101416
Drug: 0.2% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% chlorhexidine (CHX) solution
Trial: 23951692
Drug: Dexmedetomidine 1
RxNorm normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 microg/kg over 10 minutes at anesthesia induction, followed by 0.4 to 0.8 microg/kg per hour infusion during maintenance
Trial: 23951692
Drug: Remifentanil 1
RxNorm normalized name: remifentanil 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 1 microg/kg over 1 minute at anesthesia induction, followed by 0.2 to 0.4 microg/kg per minute infusion during maintenance
Trial: 17967217
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (20 mg daily)
Trial: 16004022
Drug: Ciclopirox nail
RxNorm normalized name: Ciclopirox
DrugBank: Ciclopirox (DB01188)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclopirox nail lacquer once daily for 48 weeks plus 4 weeks of terbinafine 250 mg/day, followed by 4 weeks of rest (no terbinafine), then another 4 weeks of terbinafine 250 mg/day (PLs)
Trial: 16004022
Drug: Ciclopirox nail
RxNorm normalized name: Ciclopirox
DrugBank: Ciclopirox (DB01188)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclopirox nail lacquer once daily for 48 weeks plus terbinafine 250 mg/day for 12 weeks (PL12)
Trial: 16004022
Drug: Terbinafine 250
RxNorm normalized name: terbinafine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 250 mg/day for 12 weeks (L12)
Trial: 9892253
Drug: Glycine (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycine (0.8 g/kg per day)
Trial: 9050688
Drug: Goserelin 3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin 3.75 mg
Trial: 1931396
Drug: Clonidine 2
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine 2 micrograms kg‐1 i.v. administered over 20 min
Trial: 399527
Drug: Inhaled prostacyclin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled prostacyclin (PGI2)
Trial: 31001633
Drug: 15/50 VLP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15/50 VLP vaccine formulation (15 µg of GI.1 and 50 µg of GII.4c VLPs)
Trial: 31001633
Drug: 50/50 VLP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50/50 VLP vaccine formulation (50 µg of GI.1 and 50 µg of GII.4c VLPs)
Trial: 31001633
Drug: Memory probe
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Memory probe vaccination (15 µg each of GI.1 and GII.4c VLPs with Al(OH)3)
Trial: 9742478
Drug: Pediatric powder
RxNorm normalized name: VIVONEX PEDIATRIC POWDER,PKT,51GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric powder formulation of didanosine (ddI)
Trial: 9742478
Drug: Buffered didanosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered didanosine (ddI) tablets
Trial: 8061335
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (bismuth subcitrate 120 mgx4 + amoxycillin 500 mgx4 + metronidazole 250 mgx4)
Trial: 8061335
Drug: Double therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double therapy (amoxycillin 500 mgx4 + metronidazole 250 mgx4)
Trial: 2564267
Drug: Active control
RxNorm normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active control drug (metaproterenol or cromolyn)
Trial: 4121478
Drug: Hydromorphone (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone (1.25 mg)
Trial: 4121478
Drug: Hydromorphone (0.95
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone (0.95 mg)
Trial: 9512672
Drug: Standard regional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regional therapy with radiotherapy and surgery
Trial: 9512672
Drug: Chemotherapy, surgery,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy, surgery, and radiotherapy (previously piloted approach)
Trial: 9512672
Drug: Paclitaxel, gemcitabine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel, gemcitabine, and vinorelbine in combination with cisplatin
Trial: 7844211
Drug: 16 beta‐methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 beta‐methylprednisolone (0, 16 or 60 mg/day) for 4 days from the day of oocyte retrieval
Trial: 3348163
Drug: Fluoride supplementation
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride supplementation (10 or 20 mg F/d as sodium fluoride) during bed rest weeks 6-10
Trial: 31037967
Drug: Olaparib maintenance
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib maintenance therapy after first-line chemotherapy
Trial: 31037967
Drug: Placebo maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo maintenance therapy after first-line chemotherapy
Trial: 26518420
Drug: 3-month dual
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-month dual antiplatelet therapy (DAPT) after CoCr-EES implantation
Trial: 25524969
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein plus potassium bicarbonate supplement
Trial: 19091800
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) supplementation (1.5 g/d (n‐3) LCPUFA)
Trial: 16225529
Drug: Intravesical sodium
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical sodium hyaluronate (6 weekly doses)
Trial: 8131242
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium (275 mg x 2 capsules, total 550 mg)
Trial: 30343590
Drug: IA-PRP injections
RxNorm normalized name: magnesium aluminum silicate type Ia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IA-PRP injections (2 ultrasound-guided injections)
Trial: 30343590
Drug: Corticosteroids (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (2 ultrasound-guided intra-articular methylprednisolone and lidocaine injections at a 2-week interval)
Trial: 22018126
Drug: 0.03 mg
RxNorm normalized name: biotin 0.03 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03 mg ethinyl estradiol and 3 mg drospirenone 21/7 regimen (Group 1) for 6 months
Trial: 22018126
Drug: 0.02 mg
RxNorm normalized name: escin 0.02 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02 mg ethinyl estradiol and 3 mg drospirenone 24/4 regimen (Group 2) for 6 months
Trial: 10714852
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia (TIVA) with propofol and alfentanil
Trial: 8956797
Drug: Cisplatin (CDDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (CDDP) 40 mg m-2 + Etoposide (VP16) 100 mg m-2 on days 1-3 (arm A)
Trial: 8956797
Drug: Cisplatin (CDDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (CDDP) 30 mg m-2 on days 2 and 3 + Carboplatin (CBDCA) 250 mg m-2 on day 1 + Etoposide (VP16) 100 mg m-2 on days 1-3 + Vinorelbine (NVB) 30 mg m-2 on day 1 (arm B)
Trial: 2410317
Drug: Sucrose (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (24 +/- 13 g/day)
Trial: 2410317
Drug: Sodium cyclamate
RxNorm normalized name: Sodium cyclamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cyclamate (348 +/- 270 mg/day)
Trial: 29301920
Drug: Warfarin for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin for 18 months
Trial: 20688862
Drug: Volume targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume targeted ventilation at 4 ml/kg
Trial: 20688862
Drug: Volume targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume targeted ventilation at 6 ml/kg
Trial: 6380331
Drug: Aerosol administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerosol administration of 400 micrograms beclomethasone dipropionate
Trial: 6380331
Drug: Powder administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Powder administration of 400 micrograms beclomethasone dipropionate (Rotacaps)
Trial: 28687982
Drug: ACB plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACB plus PCI (group B, ACB with 0.375% ropivacaine 30 ml + PCI with 0.2% ropivacaine 50 ml)
Trial: 28687982
Drug: ACB (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACB (group A, ACB with 0.375% ropivacaine 30 ml)
Trial: 28687982
Drug: LIA (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIA (group C, local infiltration with 0.2% ropivacaine 100 ml)
Trial: 19383058
Drug: High-dose metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metoprolol 190 mg
Trial: 19383058
Drug: Low-dose metoprolol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose metoprolol 95 mg
Trial: 19383058
Drug: All beta-blocker
RxNorm normalized name: all-trans-beta-Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All beta-blocker treatments
Trial: 11849202
Drug: Test mucoadhesive
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test mucoadhesive solution (TS)
Trial: 11849202
Drug: Reference commercial
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference commercial solution (RS)
Trial: 10634389
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) - 0.625 mg/day conjugated equine estrogen and 2.5 mg/day medroxyprogesterone acetate
Trial: 10634389
Drug: Raloxifene -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene - 60 mg/day
Trial: 10634389
Drug: Raloxifene -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene - 120 mg/day
Trial: 9193219
Drug: Topical budesonide
RxNorm normalized name: budesonide Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical budesonide powder (800 micrograms or 400 micrograms daily)
Trial: 9193219
Drug: Surgical removal
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical removal or a single injection of sustained released betamethasone (for failed therapy)
Trial: 9193219
Drug: Not applicable
RxNorm normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not applicable (monitoring phase after treatment)
Trial: 3532680
Drug: Self-administered postoperative
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered postoperative prophylactic positive expiratory pressure (S-PEP)